Back to results
US 6,191,290 B1Granted
Taxane derivatives for targeted therapy of cancer
AssigneeThe UAB Research Foundation
InventorAhmad Safavy
Life of this patent
Estimating the term…
Abstract
The present invention describes for the first time the design and synthesis of a soluble tumor-directed paclitaxel prodrug which may establish a new mode of utilization of the taxane class of anticancer agents in cancer therapy.
Claims14
A pharmaceutical compound, wherein said compound comprising a taxane moiety conjugated to a receptor ligand peptide.
Dependencies are inferred from the claim text.